Teva Pharma Industries Ltd ADR (TEVA)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NYSE
Market Cap: $51.92B
Last updated: Nov 17, 2026 at 4:32 PM ET
Teva Pharma Industries Ltd ADR (TEVA) Statistics
Teva Pharma Industries Ltd ADR (TEVA) has a market cap of $51.92B and an enterprise value of $64.56B. Its trailing P/E of 14.4x is above its 10-year median of 4.7x.
Total Valuation
Enterprise value is 24.33% above the market cap, as debt exceeds cash.
| Market Cap | $51.92B |
|---|---|
| Enterprise Value | $64.56B |
| Latest price (Nov 17, 2026) | $42.61 |
Key Dates
| Last Earnings Date | Nov 3, 2026 |
|---|---|
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 2.9x and 6.3x. Its year-end P/E ranged from 3.1x to 10.8x from 2016 to 2025.
| P/E Ratio | 14.4x |
|---|---|
| Forward P/E | 21.0x |
| P/S Ratio | 2.9x |
| Forward P/S | 3.1x |
| P/B Ratio | 6.3x |
| P/FCF Ratio | 40.8x |
| P/OCF Ratio | 29.3x |
| PEG Ratio | 1.5 |
Enterprise Valuation
Counting debt and cash, the company is valued at 30.9x EBITDA and 51.0x free cash flow.
| EV / Earnings | 127.6x |
|---|---|
| EV / Sales | 3.7x |
| EV / EBITDA | 30.9x |
| EV / EBIT | 61.2x |
| EV / FCF | 51.0x |
Price Statistics
The stock is up 67.69% over 52 weeks and trades 5.42% above its 50-day average.
| Beta (1Y) | 0.61 |
|---|---|
| 52-Week Change | +67.69% |
| 1-Month Change | +3.15% |
| 3-Month Change | +13.72% |
| 6-Month Change | +25.07% |
| 5-Year Change | +381.58% |
| 10-Year Change | -1.52% |
| Total Return (1Y) | +67.69% |
| Total Return (3Y CAGR) | +67.59% |
| Total Return (5Y CAGR) | +36.53% |
| Return vs SPY (1Y) | +59.98% |
| Max Drawdown (1Y) | -21.79% |
| Max Drawdown (3Y) | -43.70% |
| Sharpe Ratio (1Y) | 1.62 |
| Correlation with SPY (1Y) | 0.25 |
| 50-Day Average | $40.42 |
| 200-Day Average | $35.18 |
| 52-Week Range | $24.01 to $44.57 |
| RSI (14 Days) | 55.7 |
| Average Volume (20 Days) | 7.37M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 0.95x current liabilities, and total debt is 2.10x shareholder equity.
| Current Ratio | 0.95x |
|---|---|
| Quick Ratio | 0.74x |
| Debt / Equity | 2.10x |
| Debt / EBITDA | 8.20x |
| Debt / FCF | 13.53x |
| Interest Coverage | 1.22x |
Returns and Efficiency
Return on invested capital is 4.27% over the last 12 months, against a 5-year average of 4.65%.
| Return on Equity (ROE) | 6.34% |
|---|---|
| Return on Assets (ROA) | 1.26% |
| Return on Invested Capital (ROIC) | 4.27% |
| Return on Capital Employed (ROCE) | 4.29% |
| ROE (5Y Average) | -9.48% |
| ROA (5Y Average) | -1.34% |
| ROIC (5Y Average) | 4.65% |
| Asset Turnover | 0.43x |
| Inventory Turnover | 2.51x |
| Receivables Turnover | 4.70x |
| Cash Conversion Cycle | 103 days |
Scores
TEVA has an Altman Z-Score of 0.96, in the distress zone below 1.81, and a Piotroski F-Score of 8 of 9, in the strong band of 8 or 9.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 0.96 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 8 of 9 |
| Piotroski Strength | Strong |
Income Statement
Revenue of $17.23B over the last 12 months is up 2.70% from the 12 months before.
| Revenue | $17.23B |
|---|---|
| Revenue Growth (YoY) | +2.70% |
| Gross Profit | $9.22B |
| Operating Income | $1.44B |
| Pretax Income | $372.00M |
| Net Income | $506.00M |
| EBITDA | $2.04B |
| EBIT | $1.05B |
| Reported EPS (TTM) | $2.96 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 19.93% of the $40.04B in total assets.
| Cash and Equivalents | $4.08B |
|---|---|
| Total Debt | $16.72B |
| Net Debt | $12.63B |
| Working Capital | -$823.00M |
| Shareholder Equity | $7.98B |
| Tangible Book Value | -$11.07B |
| Total Assets | $40.04B |
| Total Liabilities | $32.06B |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $534.00M of capital spending, operating cash flow left $1.24B of free cash flow.
| Operating Cash Flow | $1.77B |
|---|---|
| Capital Expenditures | $534.00M |
| Free Cash Flow | $1.24B |
| FCF Per Share | $1.06 |
| Depreciation and Amortization | $985.00M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 8.33%, against a 5-year average of 1.90%.
| Gross Margin | 53.52% |
|---|---|
| Operating Margin | 8.33% |
| Pretax Margin | 2.16% |
| Net Margin | 2.94% |
| EBITDA Margin | 11.84% |
| EBIT Margin | 6.12% |
| FCF Margin | 7.17% |
| Gross Margin (5Y Average) | 48.66% |
| Operating Margin (5Y Average) | 1.90% |
| Net Margin (5Y Average) | -3.81% |
Growth
Revenue grew 4.96% a year over 3 years, and EPS 4.53% a year.
| Revenue Growth (3Y CAGR) | +4.96% |
|---|---|
| Revenue Growth (5Y CAGR) | +0.71% |
| EPS Growth (3Y CAGR) | +4.53% |
| EPS Growth (5Y CAGR) | +2.37% |
| FCF Growth (3Y CAGR) | +3.28% |
| FCF Growth (5Y CAGR) | +12.47% |
Dividends and Yields
TEVA does not pay a dividend. Its free cash flow yield is 2.45%.
| Earnings Yield | 6.94% |
|---|---|
| FCF Yield | 2.45% |
| Shareholder Yield | 0.00% |
Stock Splits
The last split was a 2-for-1 forward split on Jul 1, 2004.
| Last Split Date | Jul 1, 2004 |
|---|---|
| Split Type | Forward split |
| Split Ratio | 2:1 |
Peer Position
Against 8 similar companies, TEVA has the 6th highest P/E.
P/E RatioPeer median 19.9x
P/S RatioPeer median 2.3x
ROICPeer median 5.65%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +7.20%
| P/E Ratio | 14.4x vs 19.9x median |
|---|---|
| P/S Ratio | 2.9x vs 2.3x median |
| ROIC | 4.27% vs 5.65% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +2.70% vs +7.20% median |
Analyst Forecast
Consensus estimates put revenue growth at 2.16% and EPS growth at 7.88% a year over the next 5 fiscal years.
| Revenue Growth Forecast (5Y CAGR) | +2.16% |
|---|---|
| EPS Growth Forecast (5Y CAGR) | +7.88% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About TEVA
What is TEVA's market cap?
Teva Pharma Industries Ltd ADR has a market cap of $51.92B. Its enterprise value, which adds debt and subtracts cash, is $64.56B.
What is TEVA's P/E ratio?
Teva Pharma Industries Ltd ADR has a trailing P/E ratio of 14.4x and a forward P/E of 21.0x.
How many shares of TEVA are outstanding?
Teva Pharma Industries Ltd ADR has 1.18B shares outstanding. The count is up 1.63% from a year earlier.
Does TEVA pay a dividend?
No. Teva Pharma Industries Ltd ADR does not pay a dividend.
How much debt does TEVA have?
Teva Pharma Industries Ltd ADR has $16.72B of total debt and $4.08B of cash and equivalents, a net debt position of $12.63B.
TEVA pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors